Ligand Pharmaceuticals LGND Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's total liabilities & equity?
- Ligand Pharmaceuticals (LGND) reported total liabilities & equity of $1.53B in Q1 2026.
- How has Ligand Pharmaceuticals's total liabilities & equity changed year-over-year?
- Ligand Pharmaceuticals's total liabilities & equity increased by 69.2% year-over-year, from $905.44M to $1.53B.
- What is the long-term trend for Ligand Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's total liabilities & equity has grown at a 2.8% compound annual growth rate (CAGR), from $1.36B to $1.56B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.